临近年关,自身免疫领域迎来两笔重磅交易。12月15日,辉瑞与赛诺菲两大制药巨头相继出手,分别与Adaptive Biotechnologies及Dren Bio达成合作,潜在交易总额超26亿美元,为2025年的BD市场画上浓墨重彩的一笔。▌辉瑞和Adaptive:8.9亿美元布局TCR疗法根据协议,辉瑞将借助Adaptive的AI免疫医学平台与海量T细胞受体数据,发现类风湿关节炎(RA)相关的...
Source Link临近年关,自身免疫领域迎来两笔重磅交易。12月15日,辉瑞与赛诺菲两大制药巨头相继出手,分别与Adaptive Biotechnologies及Dren Bio达成合作,潜在交易总额超26亿美元,为2025年的BD市场画上浓墨重彩的一笔。▌辉瑞和Adaptive:8.9亿美元布局TCR疗法根据协议,辉瑞将借助Adaptive的AI免疫医学平台与海量T细胞受体数据,发现类风湿关节炎(RA)相关的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.